Keyword: Humira

Pharmaceutical ad spending continued its upward climb last year, with spending topping $6.46 billion, according to Kantar Media.

AbbVie’s Humira and Pfizer’s Xeljanz remained in the top two spots for pharma TV ad spending for the month of March.

Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.

Plaintiffs are piling into court claiming AbbVie quashed Humira competition with a "patent thicket" and an illegal “pay-for-delay" deal.

AbbVie investors are calling for a separation of powers between its board chairman and CEO roles following congressional scrutiny and patent fights over its drug Humira.

A new investigative report outlines how AbbVie worked to keep Humira market share upon the introduction of biosimilars in the Netherlands.

AbbVie's in need of a Humira follow-up, and it took one step in that direction with a Japanese approval for IL-23 inhibitor Skyrizi.

Analysts with Cortellis expect seven blockbuster drug launches in markets across the world this year. AbbVie's upadacitinib leads the pack.

AbbVie's efforts to protect Humira violate antitrust laws and consumer protection laws, a grocery union argued in a new class action lawsuit.